Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients
Background: Metabolic syndrome (MetS) has been associated with various cancers, including breast and endometrial cancer. However, its role in the severity of ovarian cancer remains unclear. This study aimed to investigate the association between MetS and the severity of ovarian ca...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-04-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/52/4/10.31083/CEOG26690 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849697394394923008 |
|---|---|
| author | Moyi Jiang Kexin Zhang Ying Jin |
| author_facet | Moyi Jiang Kexin Zhang Ying Jin |
| author_sort | Moyi Jiang |
| collection | DOAJ |
| description | Background: Metabolic syndrome (MetS) has been associated with various cancers, including breast and endometrial cancer. However, its role in the severity of ovarian cancer remains unclear. This study aimed to investigate the association between MetS and the severity of ovarian cancer. Methods: A retrospective analysis was performed on 309 ovarian cancer patients hospitalized at Beijing Friendship Hospital from January 2013 to January 2024. The Chinese Diabetes Society criteria were used to define MetS. The association between ovarian cancer severity and MetS was evaluated using multivariable logistic regression models. Results: The overall prevalence of MetS in ovarian cancer was 15.69% (48/306), with 15% (17/113) in Stage I, 10% (3/31) in Stage II, 17% (18/103) in Stage III, and 17% (10/59) in Stage IV. After adjusting for confounding variables (fully adjusted Model 3), logistic regression analysis showed that ovarian cancers in Stage II (odds ratio (OR): 0.814, 95% confidence interval (CI): 0.192–3.440), Stage III (OR: 1.121, 95% CI: 0.478–2.629), and Stage IV (OR: 1.315, 95% CI: 0.479–3.609) was not significantly associated with MetS compared to Stage I. Conclusion: MetS was not found to be associated with ovarian cancer severity. Further prospective studies are needed to determine the causal relationship between MetS and ovarian cancer severity. |
| format | Article |
| id | doaj-art-b6a33a1c753a48f187bf033d81fd2d42 |
| institution | DOAJ |
| issn | 0390-6663 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj-art-b6a33a1c753a48f187bf033d81fd2d422025-08-20T03:19:13ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632025-04-015242669010.31083/CEOG26690S0390-6663(25)02585-0Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese PatientsMoyi Jiang0Kexin Zhang1Ying Jin2Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, 100052 Beijing, ChinaDepartment of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, 100052 Beijing, ChinaDepartment of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, 100052 Beijing, ChinaBackground: Metabolic syndrome (MetS) has been associated with various cancers, including breast and endometrial cancer. However, its role in the severity of ovarian cancer remains unclear. This study aimed to investigate the association between MetS and the severity of ovarian cancer. Methods: A retrospective analysis was performed on 309 ovarian cancer patients hospitalized at Beijing Friendship Hospital from January 2013 to January 2024. The Chinese Diabetes Society criteria were used to define MetS. The association between ovarian cancer severity and MetS was evaluated using multivariable logistic regression models. Results: The overall prevalence of MetS in ovarian cancer was 15.69% (48/306), with 15% (17/113) in Stage I, 10% (3/31) in Stage II, 17% (18/103) in Stage III, and 17% (10/59) in Stage IV. After adjusting for confounding variables (fully adjusted Model 3), logistic regression analysis showed that ovarian cancers in Stage II (odds ratio (OR): 0.814, 95% confidence interval (CI): 0.192–3.440), Stage III (OR: 1.121, 95% CI: 0.478–2.629), and Stage IV (OR: 1.315, 95% CI: 0.479–3.609) was not significantly associated with MetS compared to Stage I. Conclusion: MetS was not found to be associated with ovarian cancer severity. Further prospective studies are needed to determine the causal relationship between MetS and ovarian cancer severity.https://www.imrpress.com/journal/CEOG/52/4/10.31083/CEOG26690metabolic syndromeovarian cancerobesityhypertensionhyperlipidemiaabnormal lipid metabolismhyperglycemia/type 2 diabetesinsulin resistance |
| spellingShingle | Moyi Jiang Kexin Zhang Ying Jin Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients Clinical and Experimental Obstetrics & Gynecology metabolic syndrome ovarian cancer obesity hypertension hyperlipidemia abnormal lipid metabolism hyperglycemia/type 2 diabetes insulin resistance |
| title | Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients |
| title_full | Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients |
| title_fullStr | Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients |
| title_full_unstemmed | Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients |
| title_short | Metabolic Syndrome and Ovarian Cancer Staging: A Retrospective Analysis of Chinese Patients |
| title_sort | metabolic syndrome and ovarian cancer staging a retrospective analysis of chinese patients |
| topic | metabolic syndrome ovarian cancer obesity hypertension hyperlipidemia abnormal lipid metabolism hyperglycemia/type 2 diabetes insulin resistance |
| url | https://www.imrpress.com/journal/CEOG/52/4/10.31083/CEOG26690 |
| work_keys_str_mv | AT moyijiang metabolicsyndromeandovariancancerstagingaretrospectiveanalysisofchinesepatients AT kexinzhang metabolicsyndromeandovariancancerstagingaretrospectiveanalysisofchinesepatients AT yingjin metabolicsyndromeandovariancancerstagingaretrospectiveanalysisofchinesepatients |